



May 17, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated May 17, 2024 titled **“Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX®) for the US market”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX®) for the US market

Ahmedabad, 17 May 2024

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX®) for the US market.

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX®, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the Product in the US market. MSN was a first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX®.

Speaking on the development, Managing Director of Zydus Lifesciences Ltd., Dr. Sharvil Patel said, "This partnership with MSN Laboratories underscores our commitment to provide patients with access to high-quality, affordable medications. Cabozantinib Tablets is an important treatment option for many cancer patients, and we are pleased to work with MSN to bring the generic version of CABOMETYX® to the US market."

Dr. MSN Reddy, Founder, Chairman & Managing Director - MSN Group said, "As a leading global developer and manufacturer of vertically integrated generics, we are pleased to partner with Zydus on this significant First to Market opportunity. Bringing Cabozantinib Tablets to market represents another example of MSN's global development, manufacturing, and regulatory expertise. We are confident that working with Zydus will allow us to successfully commercialize Cabozantinib while advancing our mission of enabling access to high quality, affordable medicines.

The total addressable market opportunity of Cabozantinib Tablets in US is approximately US\$ 1,464 million (IQVIA MAT Mar 2024).

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 26,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

About MSN Laboratories

MSN Laboratories is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 21 state-of-the-art manufacturing facilities (fifteen API and six finished dosage facilities) in India and USA. The Group has an integrated R&D center with around 2200 scientists for global API and formulation research & development under one roof.. With its core focus on speed and consistency in delivery, MSN is credited with 900+ national and international patents filed, 175+ ANDAs including 65 first to files, and emerged as World no. 1 in active US DMF filings. The company, with a product portfolio of 485+ APIs and 300+ formulations spanning over 35 major therapies, and has won the trust of more than 40 million patients in 80+ countries across the world. MSN products in the USA are marketed under the NOVADOZ pharma label and in the UK/EU under the Label of Vivanta Generics. MSN has strong presence in India with around 1600+ medical reps as well as in 90+ emerging markets. www.msnlabs.com

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878